Two landmark trials give CVD outcomes for diabetes drugs

Results for linagliptin and dapagliflozin

Two trials looking at cardiovascular and renal outcomes in patients on therapy for type 2 diabetes will help doctors tailor treatment better to the patient, a diabetes specialist says.